Seattle Genetics, Inc. (JOBS) in Licensing Deal with GlaxoSmithKline (JOBS); Seattle to Get $12 Million Upfront; up to $390 Million in Milestone Payments
Reuters -- Seattle Genetics Inc said GlaxoSmithKline will pay $12 million upfront for the rights to use its antibody-drug conjugate (ADC) technology, under a collaboration agreement between the two companies.